Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients
Sponsor: AstraZeneca
Participating sites:
- AZ Nikolaas, St-Niklaas
- AZ Damiaan, Oostende
- OLV Aalst, Aalst
- UZ Leuven, Leuven
- CHU UCL Namur, site Sainte Elisabeth, Namur
